4 recruiting, 3 unknown, 2 not yet recruiting, 1 completed. 10 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 4, Unknown 3, Not yet recruiting 2, Completed 1 |
| Phase 1 | 5 | Not yet recruiting 2, Recruiting 2, Completed 1 |
Follow RAS Mutation: new trials by email Literature Review of RAS Mutation trials Research Report on RAS Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation. GFH276, with or without Tislelizumab, Pemetrexed - RAS Mutation, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 84 | 2026-11-01 | 2026-09-29 |
| TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients vopimetostat, ERAS-0015 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | Tango Therapeutics, Inc. | 188 | 2026-11-01 | 2026-10-27 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 183 | 2025-05-31 | 2026-10-23 |
| ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC irinotecan, cetuximab, envafolimab - RAS Mutation, Metastatic Colorectal Cancer | Phase 2 | Recruiting | Beijing Hospital | 60 | 2024-03-01 | 2026-07-28 |
| Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer Cadonilimab + bevacizumab + FOLFOX - Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma | Phase 2 | Recruiting | Fudan University | 53 | 2024-01-01 | 2024-01-23 |
| Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab - RAS Mutation, Ras (Kras or Nras) Gene Mutation | Phase 2 | Unknown | N.N. Petrov National Medical Research Center of Oncology | 20 | 2023-10-03 | 2024-01-29 |
| NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) OKI-179 + binimetinib - RAS Mutation, NRAS Gene Mutation | Phase 1 / Phase 2 | Completed | OnKure, Inc. | 36 | 2022-05-11 | 2025-03-07 |
| PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC oxaliplatin+capecitabine+bevacizumab+PD-1 antibody - Colorectal Cancer, RAS Mutation | Phase 2 | Unknown | Chinese PLA General Hospital | 40 | 2021-05-26 | 2024-04-30 |
| Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine - Metastatic Colorectal Cancer, RAS Mutation | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 25 | 2021-02-04 | 2023-03-17 |
Colorectal Neoplasms (5) · Lung Neoplasms (3) · Melanoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Neoplasms by Site (9) · Neoplasms (8) · Colonic Diseases (5) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Intestinal Diseases (5) · Intestinal Neoplasms (5) · Rectal Diseases (5) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Neoplasms by Histologic Type (2)
Bevacizumab (2) · Cetuximab (2) · Irinotecan (2) · Carboplatin (1) · Cisplatin (1) · Fluorouracil (1) · Folfox protocol (1) · Gemcitabine (1) · Immune Checkpoint Inhibitors (1) · Leflunomide (1) · Leucovorin (1) · Oxaliplatin (1) · Pemetrexed (1) · Taxes (1) · binimetinib (1)
Genfleet Therapeutics (Shanghai) Inc. (2) · Tango Therapeutics, Inc. (2) · Beijing Hospital (1) · Chinese PLA General Hospital (1) · Fudan University (1) · N.N. Petrov National Medical Research Center of Oncology (1) · OnKure, Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
China (5) · United States (2) · Australia (1) · Russia (1)
Evgeny Imyanitov (1) · Guanghai Dai, MD (1) · Maxim Pimpkin, MD, PhD (1) · Ryan Sullivan, MD (1) · Ying Yuan, MD (1) · Ziming Li, MD (1)